全文获取类型
收费全文 | 1179篇 |
免费 | 50篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 61篇 |
妇产科学 | 64篇 |
基础医学 | 123篇 |
口腔科学 | 17篇 |
临床医学 | 93篇 |
内科学 | 271篇 |
皮肤病学 | 2篇 |
神经病学 | 44篇 |
特种医学 | 361篇 |
外科学 | 68篇 |
综合类 | 17篇 |
预防医学 | 30篇 |
眼科学 | 3篇 |
药学 | 45篇 |
中国医学 | 1篇 |
肿瘤学 | 49篇 |
出版年
2022年 | 5篇 |
2021年 | 19篇 |
2020年 | 10篇 |
2019年 | 8篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 9篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 23篇 |
2010年 | 20篇 |
2009年 | 27篇 |
2008年 | 27篇 |
2007年 | 44篇 |
2006年 | 23篇 |
2005年 | 21篇 |
2004年 | 20篇 |
2003年 | 17篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 14篇 |
1999年 | 28篇 |
1998年 | 49篇 |
1997年 | 45篇 |
1996年 | 60篇 |
1995年 | 45篇 |
1994年 | 36篇 |
1993年 | 42篇 |
1992年 | 30篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 43篇 |
1988年 | 42篇 |
1987年 | 41篇 |
1986年 | 34篇 |
1985年 | 46篇 |
1984年 | 33篇 |
1983年 | 29篇 |
1982年 | 30篇 |
1981年 | 28篇 |
1980年 | 15篇 |
1979年 | 4篇 |
1978年 | 10篇 |
1977年 | 34篇 |
1976年 | 29篇 |
1975年 | 18篇 |
1974年 | 8篇 |
1967年 | 5篇 |
排序方式: 共有1251条查询结果,搜索用时 0 毫秒
41.
42.
43.
44.
鸟氨酸脱羧酶的生理病理特点及其药物研究概况 总被引:2,自引:0,他引:2
鸟氨酸脱羧酶(ornithinedecarboxylase,ODC)是多胺代谢中的关键酶,广泛存在于人体和动物各组织细胞内,其中对肠细胞的增生、移行和分化起重要作用.机体调节因素比较复杂.在黏膜损伤性疾病及某些癌前病变等细胞大量增生的病理情况下ODC的表达发生改变,可以作为这些疾病分期、预后及药物作用靶点或疗效的指标.寻找对ODC有作用的药物对于治疗其相关疾病是非常有意义的. 相似文献
45.
46.
47.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
48.
49.
Walenga JM Jeske WP Samama MM Frapaise FX Bick RL Fareed J 《Expert opinion on investigational drugs》2002,11(3):397-407
Fondaparinux (Arixtra, Sanofi-Synthélabo/Organon) is the first of a new class of antithrombotic agents distinct from low molecular weight heparins (LMWHs) and heparin. It is a chemically synthetic pentasaccharide mimicking the site of heparin that binds to antithrombin III (AT). It exhibits only factor (F) Xa (FXa) inhibitor activity via binding to AT, which in turn inhibits thrombin generation. In contrast to heparin and LMWH, plasma anti-Xa activity corresponds directly to levels of fondaparinux. It does not release tissue factor pathway inhibitor (TFPI). There is nearly complete bioavailability by the sc. route, rapid onset of action, a prolonged half-life in both iv. and sc. (14 - 20 h) dosing regimens and no metabolism preceding renal excretion. Phase IIb clinical studies have identified a dose of 2.5 mg once-daily for prophylaxis of venous thrombosis. Four Phase III studies (n > 7000) have demonstrated a combined 50% relative risk reduction of venous thromboembolic events in orthopaedic surgery patients in comparison to the LMWH, enoxaparin. Haemmorrhagic complications for fondaparinux were either comparable to or higher than those for LMWH. The activated partial thromboplastin time (aPTT) is not affected by fondaparinux. At present, laboratory monitoring is not recommended. Clinical trials for treatment of established thrombosis, coronary syndromes and adjunct to thrombolytic therapy are in progress. 相似文献
50.
Green J Assady S Nakhoul F Bick T Jakobi P Abassi Z 《Journal of the American Society of Nephrology : JASN》2000,11(7):1188-1198
The clinical features of preeclampsia have been traditionally ascribed to a generalized vascular endothelial cell dysfunction. The present study investigates the effect of sera from preeclamptic women and normal pregnancy on the metabolism of intracellular Ca(2+) concentration ([Ca(2+)](i)) in normal cultured vascular smooth muscle cells (VSMC). Sera were obtained from normotensive pregnant women (NTP) (n = 17), preeclamptic women (PE) (n = 15), pregnant women with chronic (essential) hypertension (pregnant EHT) (n = 8), non-pregnant women with essential hypertension (non-pregnant EHT) (n = 12), and age-matched non-pregnant normotensive women (NNP) (n = 18). Serum (10%) was applied to both primary cultures of rat aortic smooth muscle cells and to the A-10 vascular muscle cell line. Levels of [Ca(2+)](i) were determined fluorometrically. After a 4-h incubation with serum, basal [Ca(2+)](i) was not significantly altered. However, compared with normal pregnant sera, PE sera markedly reduced hormonally induced Ca(2+) transients. Thus, following acute stimulation of rat VSMC (primary cultures) with 10(-8)M angiotensin II, peak [Ca(2+)](i) responses (% increment over baseline) were 443 +/- 22, 184 +/- 18, 259 +/- 12, 274 +/- 23, and 255 +/- 15% in NTP, PE, pregnant EHT, non-pregnant EHT, and NNP, respectively (P <0.01 PE versus NTP, P <0.05 PE versus NNP and pregnant and non-pregnant EHT). These effects of sera on [Ca(2+)](i) were qualitatively reproduced in platelets obtained from healthy volunteers. Also, depolarization-activated Ca(2+) influx in VSMC was affected by the different sera groups in a manner similar to that seen with hormonally induced [Ca(2+)](i) responses. The altered [Ca(2+)](i) changes by PE sera disappeared 5 wk after delivery. The effect of the different sera groups on hormonally triggered Ca(2+) transients in normal VSMC, as well as the normalization of [Ca(2+)](i) responses after delivery, suggest the presence of a circulating serum factor in PE. Inasmuch as [Ca(2+)](i) is the major determinant of VSMC tone, it is possible that consequent to the attenuation of [Ca(2+)](i) responses, this putative circulating factor counterbalances the intense vasoconstriction in PE. 相似文献